CompletedPhase 1NCT00004932
STI571 in Treating Patients With Recurrent Leukemia
Studying Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Martin Champagne, MD, MDHopital Sainte Justine
- Intervention
- imatinib mesylate(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2002 – 2005
Study locations (30)
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
- University of South Alabama Medical Center, Mobile, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arizona Cancer Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Southern California Permanente Medical Group, Downey, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Jonathan Jaques Children's Cancer Center, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Children's Hospital Central California, Madera, California, United States
- Children's Hospital of Oakland, Oakland, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00004932 on ClinicalTrials.govOther trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05031897Two Step Haplo With Radiation ConditioningThomas Jefferson University
- ACTIVE NOT RECRUITINGPHASE2NCT04188405Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT02530034Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT03630991Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT03147612Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT02861417Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantM.D. Anderson Cancer Center
See all trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2) →